GtoPdb Ligand ID: 9601

Synonyms: AL-3818 | AL3818 | anlotinib
catequentinib is an approved drug (China (2018))
Compound class: Synthetic organic
Comment: Catequentinib (AL3818; anlotinib) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123 [2].
Note that anlotinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but has not been submitted to the World Health Organisation for ratification, and in fact a genuine INN request for 'catequentinib' was submitted for this chemical structure to the WHO (in Proposed List 121) and this became the recommended INN in April 2020..
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 82.39
Molecular weight 407.16
XLogP 3.48
No. Lipinski's rules broken 0
Canonical SMILES COc1cc2c(ccnc2cc1OCC1(N)CC1)Oc1ccc2c(c1F)cc([nH]2)C
Isomeric SMILES COc1cc2c(ccnc2cc1OCC1(N)CC1)Oc1ccc2c(c1F)cc([nH]2)C
InChI InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
No information available.
Summary of Clinical Use
Catequentinib (AL3818) is a clinical candidate for a number of advanced solid tumour types. Click here to link to's full list of AL3818 studies. In May 2018, the China National Medical Products Administration (NMPA) approved anlotinib, as a treatment for patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior systemic chemotherapy [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02072031 Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma(RCC) Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02558348 Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Phase 1/Phase 2 Interventional Advenchen Laboratories, LLC
NCT02809534 A Study of Anlotinib in Patients With Hepatocellular Carcinoma Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03016819 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Phase 3 Interventional Advenchen Laboratories, LLC